FDA Clearance Tracker · P150031-S011
Vercise Gevia DBS System and Directional Lead-only System
Last checked: Nov 20, 2026Latest source record: Aug 19, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Aug 19, 2019
Approved
Time to decision
200 days
Received Jan 31, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P150031-S011
- Device name
- Vercise Gevia DBS System and Directional Lead-only System
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Jan 31, 2019
- Decided
- Aug 19, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150031
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for MR Conditional labeling of the Vercise Gevia Deep Brain Stimulation (DBS) System.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.